Katri Aaltonen

Katri Aaltonen

Auto-generated profile, based on publicly available information

Katri Aaltonen

INVEST Research Flagship Centre, University of Turku, Turku, Finland

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
RRRajan Ragupathy
Rajan Ragupathy
KAKatri Aaltonen
Katri Aaltonen
JTJune Tordoff
June Tordoff
PNPauline Norris
Pauline Norris
DRDavid Reith
David Reith

1 January 2010 in Value in Health
Verified
Journal Article
Closed access
KAKatri Aaltonen
Katri Aaltonen
RRRajan Ragupathy
Rajan Ragupathy
JTJune Tordoff
June Tordoff
DRDavid Reith
David Reith
PNPauline Norris
Pauline Norris

12 November 2014 in European Journal of Public Health
Verified
Journal Article
Closed access
PDF file
KAKatri Aaltonen
Katri Aaltonen
JMJani Miettinen
Jani Miettinen
IAIlpo Airio
Ilpo Airio
JMJaana E. Martikainen
Jaana E. Martikainen
LSLeena K. Saastamoinen
Leena K. Saastamoinen
PNPauline Norris
Pauline Norris
Background: The objective was to examine cost-related barriers to using health services and prescription medicines in Finland. Methods: A survey that examined adults’ experiences of and opinions about the social security system was mailed to a random population-based sample of 5000 Finns aged 18–74 years. The survey assessed households’ cost-related barriers to use of health services, prescription medicines and social assistance in the past year. The responses were adjusted for sociodemographic and health predictors by weighting and logistic regression. Results: Responses were received from 1770 households. In total, 18% had experienced at least one cost-related barrier; 11% did not fill a prescription, 8% did not go to hospital and 13% went without another form of treatment. Of respondents diagnosed with a disabling illness or impairment, 32% reported at least one cost-related barrier. Households with below-average income reported barriers twice as often as above-average income households, after adjusting for age and health. Lower income [lowest tertile, odds ratio (OR) 5.0 compared with highest tertile], fair/poor self-assessed health (fair/poor OR 7.1 compared with very good/good), younger age (18−34 years OR 3.8 compared with 65−74 years), lower education (primary OR 1.6 compared with tertiary) and female gender (OR 1.4) were significantly associated with more frequent cost-related barriers. Overall, 34% of households who encountered cost-related barriers had applied for and 17% had received social assistance. Conclusions: Cost-related barriers were common among respondents with low income and/or poor health. These barriers may thus have a role in creating inequities in access to health care in Finland.

18 September 2018 in Health Policy
Verified
Journal Article
Closed access
ASAarni Soppi
Aarni Soppi
PHPekka Heino
Pekka Heino
TKTerhi Kurko
Terhi Kurko
TMTimo Maljanen
Timo Maljanen
LSLeena Saastamoinen
Leena Saastamoinen
KAKatri Aaltonen
Katri Aaltonen

1 September 2021 in Health Policy
Verified
Journal Article
Open access
HRHanna Rättö
Hanna Rättö
TKTerhi Kurko
Terhi Kurko
JMJaana E. Martikainen
Jaana E. Martikainen
KAKatri Aaltonen
Katri Aaltonen
International literature suggests that co-payment increases are associated with decreased medicine use, although the effects depend on context. We examined the impact of a co-payment increase on the consumption of type 2 antidiabetics in Finland, a country with a comprehensive health and social security system including ceiling mechanisms aiming to protect patients from high co-payment expenditures. We used administrative register data on all reimbursed purchases of antidiabetics during 2014-2018. An interrupted time series design with segmented regression was used to examine the mean monthly purchase per person, measured as Defined Daily Doses (DDDs), before and after the co-payment increase. At baseline, the mean monthly purchase per person of type 2 antidiabetics was 105 DDDs (95% CI 103.8; 106.0;p<0.001) and there was a decreasing trend of 0.2 DDDs per month (95% CI -0.23;-0.13;p<0.001). A statistically significant decrease of 5.6 DDDs (95% CI -7.3;-3.8;p<0.001) was detected after the reform; however, no significant change in the trend was observed. No significant increase was detected in the mean monthly per person purchase of insulins. The results suggest that a co-payment increase decreases consumption of necessary medicines despite the presence of a medicine co-payment ceiling mechanism. Whether the decrease was associated with negative health effects remains to be further investigated.